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Abstract
Latency Associated Peptide (LAP) binds TGF-b1, forming a latent complex. Currently, LAP is presumed to function only as a
sequestering agent for active TGF-b1. Previous work shows that LAP can induce epithelial cell migration, but effects on
leukocytes have not been reported. Because of the multiplicity of immunologic processes in which TGF-b1 plays a role, we
hypothesized that LAP could function independently to modulate immune responses. In separate experiments we found
that LAP promoted chemotaxis of human monocytes and blocked inflammation in vivo in a murine model of the delayed-
type hypersensitivity response (DTHR). These effects did not involve TGF-b1 activity. Further studies revealed that disruption
of specific LAP-thrombospondin-1 (TSP-1) interactions prevented LAP-induced responses. The effect of LAP on DTH
inhibition depended on IL-10. These data support a novel role for LAP in regulating monocyte trafficking and immune
modulation.
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Introduction
Transforming Growth Factor-Beta 1 (TGF-b1, NM_011577)
has diverse effects in multiple cell types. It is intimately involved in
cell growth, differentiation, and immune modulation. [1,2]
Pathologic activation of TGF-b1 is associated with the develop-
ment of fibrosis[3–5] while deficiency in TGF-b1 is associated with
increased inflammatory cell trafficking and inflammation.[6,7] As
a result, TGF-b1 is characterized as an anti-inflammatory and
pro-fibrotic growth factor. Curiously, while TGF-b1 is considered
an anti-inflammatory cytokine, it induces leukocyte recruit-
ment.[8,9]
TGF-b1 activity is controlled predominantly through activation
of the latent molecule. After post-translational processing, TGF-b1
binds non-covalently to the latency associated peptide (LAP) to
confer latency.[10] This small latent complex exists without or
with latent TGF-b1 binding protein (LTBP), which is involved in
the release and targeting of TGF-b1 to the extracellular
matrix.[10,11] The non-covalent interactions between these
molecules can be disrupted by heat, extremes of pH and other
chaotropic factors in vitro, but in vivo ¸ disruption of the physical
interactions between LAP and TGF-b1 appears central to
activation.[12,13] Because of its critical role in modulating TGF-
b1 activity, LAP plays a pivotal role in regulating some of the
diverse effects of TGF-b1. In fact, LAP has been shown to be
expressed on immature dendritic cells and play a role in T cell
differentiation.[14] Previous work shows that LAP can induce
epithelial cell migration,[15,16] but effects on leukocyte recruit-
ment have not been reported. Using an animal model of skin
fibrosis with associated inflammation, in vivo treatment with LAP
abrogates fibrosis but does not affect leukocyte infiltration[5],
raising the possibility that LAP may independently stimulate
inflammatory cell recruitment.
We hypothesized that LAP independently modulated immune
cell function. Using in vivo murine models and in vitro human cell
studies, we found that LAP had both chemotactic and anti-
inflammatory activity independent of active TGF-b1.
Methods
Cell isolation
Monocyte isolation. Freshly isolated human peripheral
blood monocytes were used for these experiments. Human blood
samples were collected from healthy volunteer donors. Freshly
drawn whole blood or buffy coat preparations were used and the
isolation was performed as described previously.[17] Monocytes
used in chemotaxis assays were maintained in media (RPMI with
5% FBS) until the experiment was performed and then they were
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(Sigma-Aldrich, St Louis, MO) without serum. All monocyte
suspensions were treated with polymyxin B at 10 mg/ml. (Sigma-
Aldrich, St Louis, MO)
Macrophage Isolation and Culture. Bone marrow-derived
macrophages (BMM) were obtained from thrombospondin-1 2/2
(MGI:98737)or wild-type C57BL/6 mice. Briefly, bone marrow
progenitor cells were flushed out of the bone marrow using ice-
cold RPMI medium. The resulting isolate was then plated in
RPMI supplemented with 10% FBS, penicillin/streptomycin and
amphotericin B, 10 mg/ml polymyxin B and 20 ng/ml M-CSF.
Cells were cultured in 37uC for 5 days with the addition of 20 ng/
ml M-CSF daily. After twenty-four hours, non-adherent cells were
removed and the remaining cells were cultured to generate
macrophages. After isolation, BMM were serum starved for 12 to
16 hours at 37u C before being used for chemotaxis studies.
Cellular recruitment assays
Matrigel plug assay. Six-week-old C57BL/6 female mice
were anesthetized with isoflurane and subcutaneously injected
with 0.5 ml growth factor-reduced Matrigel
TM (BD Biosciences/
Discovery Labware, San Jose, CA) matrix supplemented with
either PBS (negative control for chemotaxis), 10 ng/ml CCL2
(positive control for chemotaxis) or 10 pg/ml of rhLAP. After 10
days the mice were sacrificed, skinned, and the Matrigel
TM plugs
were removed and placed in formalin for 24 hours. After, the
formalin was discarded and replaced with PBS. The samples were
paraffin-embedded and three sections per plug were cut and
adhered to slides for subsequent staining using Hematoxylin &
Eosin (H&E) for total cell influx into the plugs, stained for CD68+
cells (mononuclear phagocytes) with the respective isotype control
antibody stains done as well. Ten high power fields were
photographed per condition and CD68+ cells counted in a
blinded fashion.
Recruitment chamber assay. A 48-well chemotaxis chamber
(Neuroprobe, Rockville, MD) was used for all chemotaxis assays.
Recombinant human latency associated peptide (LAP, R&D
Systems, Minneapolis, MN) was cleared of endotoxin by the use of
END-X B15 beads (endotoxin-binding resin, Woods Hole
Associates, Woods Hole, MA) and suspended in media containing
polymyxin B (10 mg/ml) (Sigma-Aldrich, St Louis, MO). TGF-b1
used was also obtained from R&D Systems and was tested in systems
with polymyxin B. The tested solution (28 ml) was loaded into the
bottom well and a monocyte suspension (1610
6 cells/ml) was added
to the upper chamber (45 ml). The chamber was incubated at 37u C
and 5% CO2 for 90 minutes. Experimental conditions were
performed in at least triplicate.
Chemotaxis was measured on a 5-micron pore polycarbonate
filter specifically designed for chemotaxis assays using modified
Boyden chambers (GE Osmonics, Minnetonka, MN). The filters
were then removed, fixed and stained in Diff-quikH solution
(Fisher Scientific, Fairlawn, NJ) and viewed under a microscope.
Five blinded high-power fields were counted, averaged, and
reported as the number of monocytes/high power field. These
methods are as previously published for TGF-b1-induced
monocyte chemotaxis.[9]
In some studies, recombinant human LAP (rhLAP) or active
TGF-b1 (R&D Systems, Minneapolis, MN) was incubated with
TGF-b1, rhLAP, anti-LAP, anti-TGF-b1 antibodies or isogenic
control (all antibodies 1 mg/ml) for thirty minutes prior to the
addition of the monocyte suspension. For other inhibitor studies
looking at interactions with LAP that were tested in chemotaxis
assays, the monocyte suspension was incubated with the
appropriate antibody (1 mg/ml), peptide (20 mM LSKL and
GRGDSP), signal inhibitor (U0126, 5 mM and SB 431542,
5 mM and 10 mM) or control (isotype antibody at 1 mg/ml or
scrambled peptide, 20 mM SLLK and GRGESP) for thirty
minutes prior to washing and using in chemotaxis studies.
Directed-recruitment (Chemotaxis) assay. Similar
experiments were performed to the recruitment assays described
above, except that the potential gradient of LAP was obliterated
with adding equal amounts of LAP to both the upper well
(monocyte suspension) and lower well (chemoattractant chamber).
This was performed to assure that monocyte migration mediated
by LAP was chemotaxis. In these studies a concentration of the
tested agent (LAP) was added to the lower well only or to the
upper and lower well. The monocyte suspension was placed in the
upper well only. If a non-specific increase in cell motility was the
true response of monocytes to exposure to LAP, increased
monocyte numbers would still be seen in the LAP exposed
monocytes despite the existence of a zero effective gradient to
direct migration.
Inhibitors. LSKL and SLLK were kindly provided by Pravin
Kaumaya (The Ohio State University) while RGD blocking
peptide (G4391, GRGDS) and scramble control peptide (A5686,
RGES acetate salt) were from Sigma-Aldrich (St Louis, MO) and
LAP-derived RGD sequence (GRGDSP) and control peptide
(GRGESP) were from Invitrogen (Carlsbad, CA). Anti-LAP
(MAB-246, clone 27235.1) and anti-TGF-b1 (MAB-240)
antibodies were from R&D systems (Minneapolis, MN). Anti-
CD36 IgG (Ab-2, clone 185-162) and anti-CD47 (Ab-2, clone
B6H12.2) were from Neomarkers (Fremont, CA).
Thrombospondin-1 antibody (clone A6.1, BA-24) was from
Calbiochem (Fremont, CA). Polyclonal mouse IgG (polyclonal
mouse IgG, sc-2025) was from Santa Cruz Biotechnology, Santa
Cruz, CA. SB 431552 was from Sigma-Aldrich (St Louis, MO).
Finally, U0126 was from Calbiochem (Fremont, CA).
Murine delayed-type hypersensitivity response transfer
assay
We previously published a method of measuring in vivo delayed
type hypersensitivity using a mouse model of antigen and immune
response transfer that is inhibited by TGF-b1.[18] Wild-type mice
(C57BL/6) were tested for DTH responses using a transfer DTH
assay. For this assay, the pinnae of naı ¨ve C57BL/6 mice were
injected using a 30-gauge insulin syringe with 35 ml of a mixture
containing 8610
6 splenocytes from tetanus toxin-sensitized mice
plus tetanus toxin with or without 5 ng of porcine TGF-b1 (R&D
Systems) or 10 pg of human LAP (R&D Systems). Alternatively,
this assay was repeated using C57BL/6 mice that had rejected a
cardiac allograft (DBA/2-.C57BL/6, ‘‘rejector’’ mice) as a model
of allograft DTHR. This model has been shown to yield similar
results to the DTH model.[19] DTHR was induced in the pinnae
of naı ¨ve C57BL/6 mice with simultaneous injection of subcellular
DBA/2 alloantigen (35 ml) and splenocytes (8610
6cells/condition)
harvested from these sensitized ‘‘rejector’’ mice between 30–60
days post transplant. In other experiments, 10 mg of anti-
thrombospondin-1 rabbit polyclonal antibodies (Neomarkers,
Fremont, CA), 25 mg of anti-IL10 goat polyclonal antibodies
(BD Biosciences) or isogenic control IgG were also included in the
DTH injection mixture.
Alternatively, tetanus-sensitized C57BL/6 thrombospondin-1 -/-
mice were tested for DTH responses between 14–28 days post-
tetanus sensitization using a direct DTH assay. For this assay, the
pinnae of the sensitized mice were injected using a 30-gauge insulin
syringe,with a 35 mlm i x t u r eo f2 5ml (limit of flocculation) oftetanus
toxoid (Adventis, Stillwater, PA) 65n go fp o r c i n eT G F - b1( R & D
Systems) or 10 pg of rhLAP (R&D Systems). Changes in ear
Immune Effects of LAP
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injection and 24 hours after injection using a dial thickness gauge
(Swiss Precision Instruments, Carlstadt, NJ). For reference, changes
in the range of 0–30 610
24 inches represent background swelling
duetoinjectiontrauma,changesinthe rangeof40–60610
24 inches
represent moderate DTH response, and changes in the range of 70–
100 610
24 inches represent strong DTH responses.[20]
Macrophage stimulation
Murine macrophages (RAW 264.7 cells) were grown in sterile
conditions. Wells were then washed to remove all non-adherent
cells and serum starved overnight at 37uC. The cells were then
stimulated with equal molar of LAP (100ng/ml), TGF-b1 (36ng/
ml), latent TGF-b1 (121ng/ml) or control M-CSF (100 ng/ml) for
10 minutes. Cells were lysed, protein quantitated, and Western
Blotted for phospho-Smad 2/3 (Cell Signaling Technology,
Danvers, MA), then re-probed for total Smad 2/3.
Statistical analysis
For all studies, one-way ANOVA was used to test for significant
(p-value of ,0.05) differences in the analyzed data. Post-hoc
analysis was used to differentiate individual differences reflected in
the group. Tukey’s pairwise comparison was used for chemotaxis
assays, while Fisher’s pairwise was used for DTHR transfer assays.
All analyses were run on MinitabH statistical software (State
College, PA).
All human studies were approved by the Ohio State University
Biomedical IRB. Animal studies were performed only after
approval of the research plan by the Institutional Animal Care
and Use Committee at The Ohio State University.
Results
LAP is a monocyte chemoattractant
To evaluate the biological effects of LAP, we first studied
monocyte chemotactic activity. To test this in vivo, Matrigel
TM
plugs impregnated with LAP were inserted into the subcutaneous
tissues of mice. LAP-supplemented plugs recruited more CD68
positive cells than control plugs injected with PBS (Figure 1A–D).
To understand this observation, in vitro studies of human monocyte
chemotaxis to LAP were performed. Recombinant human LAP
induced a dose-dependent increase in monocyte recruitment
compared to vehicle-treated monocytes (p,0.001) (Figure 1E).
Monocyte recruitment occurred when a true gradient of LAP
(p,0.001) existed, but was abrogated by equilibrating LAP
concentrations across the chemotaxis membrane, suggesting that
LAP promoted monocyte chemotaxis and not chemokinesis
(Figure 1F). In addition, human monocytes did not migrate to
an irrelevant stimulus like the neutrophil chemoattractant, IL-8
(3.260.5 cells/high powered field for IL-8 vs. 2.760.37 cells/high
powered field for media alone [mean6SEM]) and vigorously
responded to a positive control like CCL2 under both anti-LAP
antibody-treated (64.463.7 cells/high powered field [mean6-
SEM]) and control IgG-treated conditions (63.663.6 cells/high
powered field [mean6SEM]). Interestingly, at 0.4 pM (10 pg/ml
equivalent) equimolar concentrations of CCL2 and LAP, LAP
induced about 2-fold more monocyte chemotaxis than CCL2, but
at 1.2 mM (10 ng/ml) equimolar concentrations, CCL2 was
significantly better at inducing monocyte chemotaxis than LAP
(data not shown).
LAP-induced chemotaxis is not mediated by TGF-b1
Even though LAP used in these studies was a recombinant
human protein, to ensure that monocyte chemotaxis induced by
LAP did not involve endogenous active TGF-b1, we assessed
whether a variety of TGF-b1 inhibitors could affect LAP-induced
chemotaxis. Chemotaxis to LAP was blocked by anti-LAP
antibodies (Table 1, p,0.05), but not by equivalent concentrations
of anti-TGF-b1 neutralizing antibodies. In contrast, monocyte
chemotaxis induced by active TGF-b1 was inhibited by anti-TGF-
b1 antibodies, but not by anti-LAP antibodies. Isogenic control
antibodies did not suppress LAP- or TGF-b1-mediated chemo-
taxis. Finally, using a specific receptor kinase inhibitor, we show
that inhibiting TGF-bR1 signaling abrogates TGF-b1-induced
monocyte recruitment without affecting LAP-induced chemotaxis.
(Figure 1G) Separately, using bone-marrow derived macrophages
we were able to show that LAP did not induce SMAD activation,
whereas TGFb1 did (data not shown). These data confirm that
LAP has chemotactic activity for human monocytes in vitro
independent of TGF-b1.
TGF-b1 can inhibit LAP-induced monocyte chemotaxis
In preliminary experiments we discovered that a 1:1 molar ratio
of TGF-b1 and LAP reduced monocyte recruitment (data not
shown). Knowing that LAP in vitro limits TGF-b1 activity, we
hypothesized that TGF-b1 functioned similarly toward LAP
activity. To explore this further, we performed chemotaxis assays
using either TGF-b1 or LAP at their maximal recruitment doses
alone or with increasing molar ratios of its partner. We identified
that active TGF-b1 inhibited LAP-induced monocyte chemotaxis
(Figure 2A) just as LAP could also inhibit TGF-b1-induced
monocyte chemotaxis (Figure 2B). Interestingly at peak chemo-
tactic doses, TGF-b1 was a more potent inhibitor of LAP (10:1
molar ratio) than LAP was of TGF-b1 (1000:1 molar ratio). To
confirm that TGF-b1 inhibition of LAP-induced recruitment was
independent of TGF-b receptor activity we repeated these
experiments in the presence of a TGF-b receptor inhibitor
(Figure 2C). The experiments demonstrate that TGF-b1
induced inhibition of LAP is not mediated through the TGF-b1
receptor.
The tetrapeptide LSKL, anti-thrombospondin-1
antibodies, and the MEK inhibitor block LAP-induced
monocyte chemotaxis
Integrins often play a role in cellular migration.[21] To
investigate the role of integrins in monocyte migration to LAP,
experiments using RGD blocking peptides to modulate cellular
recruitment were performed. RGD blocking peptides did not
reduce LAP-mediated chemotaxis (Table 1). Because thrombos-
pondin-1 interacts with LAP to regulate TGF-b1 function,[13,22]
we performed experiments to determine if these interactions were
important in regulating the biologic activity of LAP. To determine
the importance of TSP-1 in LAP-induced monocyte recruitment,
anti-TSP-1 antibodies were used. Anti-TSP-1, but not isogenic
control IgG, blocked monocyte recruitment to LAP (Table 1)
(p,0.01). Because CD36 is expressed on human monocytes and
interacts with TSP-1, anti-CD36 antibodies were tested to
determine its role in LAP-induced cellular recruitment. Anti-
CD36 IgG, but not isogenic control IgG, blocked monocyte
recruitment to LAP (Table 1) (p,0.001). CD47 associates with
integrins and binds the c-terminal region of TSP-1 so its role was
explored. Similar to RGD peptides, pre-incubation with CD47-
blocking IgG did not affect LAP-mediated monocyte chemotaxis
(Table 1). Control experiments demonstrated that none of the
inhibiting antibodies affected the monocyte response to CCL2,
providing support that the inhibitory pathway tested was specific
to an LAP-mediated process (data not shown). These data
Immune Effects of LAP
PLoS ONE | www.plosone.org 3 April 2008 | Volume 3 | Issue 4 | e1914Figure 1. Latency-associated peptide (LAP) induces monocyte chemotaxis via a pathway distinct from TGF-b1. C57BL/6 female mice
were anesthetized and subcutaneously injected with Matrigel
TM matrix supplemented with PBS, rhLAP or CCL2/MCP-1. After 10 days the mice were
sacrificed, skinned, and the plugs were removed, fixed and embedded in paraffin then stained for CD68+ cells (mononuclear phagocytes). Matrigel
matrix supplemented with (A) PBS, (B) 10 pg/ml rhLAP, or (C) 10 ng/ml CCL2 were assessed for CD68+ cell recruitment and then quantified by
blinded counts (D). Arrow heads indicate CD68+ cells. (*p,0.05 for condition vs. PBS control plugs, n=3 for CCL2 and n=2 for LAP) Human
monocytes (5610
4/condition) were suspended in Gey’s balanced salt solution and assayed for their chemotactic response to rhLAP. Recruitment was
assayed by incubating monocytes in modified Boyden chambers for 90 minutes at 37uC and quantified by counting five high-powered fields of
stained membranes in a blinded fashion. (E) Increasing doses of rhLAP (0-100 pg/ml) were used to stimulate monocyte recruitment ({p,0.001 from
Immune Effects of LAP
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activity of LAP.
To further define the role of TSP-1 in LAP stimulation, known
sites of direct interaction between LAP and TSP-1 were explored.
Two important sites of interaction on TSP-1 that interact with
latent TGF-b1 are contained in the thrombospondin type 1 repeat
(TSR) region of TSP-1.[23,24] One of these regions, the
tetrapeptide motif K
412RFK
415 is important for latent TGF-b1
activation and interacts directly with a defined region of LAP
(L
54SKL
57).[25] To analyze this specific interaction between LAP
and TSP-1 in monocyte chemotaxis, the synthetic peptide LSKL
was used as a domain specific competitive inhibitor of these two
molecules. When monocytes were pre-incubated with LSKL,
monocyte chemotaxis to LAP was reduced (p,0.01), while
equivalent concentrations of the scrambled peptide SLLK did
not affect LAP-induced monocyte chemotaxis (Table 1). These
data further support the importance of the interaction between
LAP and TSP-1 in LAP-induced chemotaxis.
Because CD36 inhibition effectively blocked LAP-induced
chemotaxis and TSP-1 engagement produces activation of the
MAPK pathway[26], we used a MEK inhibitor (U0126) in a
functional chemotaxis assay with LAP. We found that U0126
inhibited LAP-induced chemotaxis (p,0.01) where DMSO alone
did not (Table 1) suggesting that the Erk/MAPK pathway was
relevant to LAP-induced monocyte activation.
LAP reduces swelling in a DTHR murine ear model
TGF-b1 has well characterized immunosuppressive effects on
leukocytes.[7,27,28] To determine if LAP mediated immunosup-
pressive effects in vivo, experiments were designed to establish
if LAP independently affected cellular inflammation. Using a
well-characterized murine model of allogeneic delayed-type
hypersensitivity (DTHR) inflammation of the pinnae, both
recombinant human (rh) LAP and (rh) active TGF-b1 reduced
inflammation measured by ear swelling (p,0.001 for either
treatment versus vehicle control) (Figure 3A). While TGF-b1
inhibits DTHR in this murine model,[20] finding that LAP
mimicked these effects is novel. Furthermore, anti-LAP IgG
reversed LAP-mediated suppression of DTHR (p,0.01) whereas
anti-TGF-b1 antibodies or control IgG did not (Figure 3A).
Based on the pathways found to be important in LAP-mediated
monocyte recruitment, the role of TSP-1 in LAP-induced inhibition
of DTHR was explored. Anti-TSP-1 antibodies were injected along
with antigen into sensitized animals. TSP-1 antibodies reversed
LAP-induced inhibition of DTHR (p,0.01) while control IgG did
not (Figure 3B). Importantly, this effect was reliant on LAP, because
when antigen and anti-TSP-1 antibodies were injected locally
without LAP, no effect was seen in the elicited DTHR (data not
shown). In separate studies, the peptide,LSKLreversed the effects of
LAP on DTHR (p,0.01) (Figure 3C), while equivalent concentra-
tions of the scrambled peptide SLLK did not. CD36 appeared to
play less of a role in this immunologic effect as anti-CD36 antibodies
only showed a trend toward interference with LAP-mediated
inhibition of DTHR, and the reversal appeared incomplete [DTH
thickness 616 2610
24in (control) vs. 1963610
24in (LAP alone) vs.
2862610
24in (LAP+ anti-CD36 Ab), p=0.058].
Previous work has shown that IL-10 and TGF-b1 are critical
mediators of the suppression of the DTH response in this
experimental system.[29] While inhibiting TGF-b1 with a
blocking antibody (Figure 3A) did not change the LAP effect,
co-incubation with IL-10 blocking antibodies prevented LAP from
blocking the DTH response (p,0.01, Figure 3D). In contrast,
isogenic antibodies did not interfere with the effects of LAP on
DTHR. This data suggests that IL-10 is a critical downstream
effector of this observed LAP effect.
Macrophages and mice lacking TSP-1 are insensitive to
the immune regulatory effects of LAP
To confirm that TSP-1 was essential to the biological function of
LAP, bone marrow-derived macrophages (BMM) from TSP-1
deficient or wild type mice were utilized in chemotaxis assays to
assess their responsiveness to LAP. BMM from C57Bl/6 wild-type
mice with functional TSP-1 migrated towards rhLAP (p,0.001)
(Figure 4A). In contrast, BMM from C57Bl/6 thrombospondin-1
2/2 mice had no significant increase in recruitment in response to
LAP compared to control conditions (Figure 4A). Importantly, TSP-
1 2/2 macrophages responded to a known positive stimulus.
the non-stimulated sample, n=7). (F) Analysis for evidence of directed recruitment of monocytes by LAP was assessed by exposing monocytes to a
‘‘true’’ gradient of rhLAP (10 pg/ml) (rhLAP in the chamber opposite the monocytes only; dark bars–‘‘Monocytes’’) or no gradient (rhLAP on both sides
of the chamber; lighter bars–‘‘Monocytes+LAP’’). These data represent two independent studies done in triplicate (*p,0.001 vs. mono + LAP
condition). (G) Assessment of LAP-specific chemotaxis was performed by pre-incubating cell suspensions with the SB 431542 hydrate from Sigma
(St.Louis, MO), a selective inhibitor of TGF-b type 1 receptor kinases (Activin Receptor-Like Kinases, ALK-4,-5, and-7) 20 minutes prior to loading on
chemotaxis chambers. Monocytes were then exposed to optimal chemotactic doses of LAP (10 pg/ml) and TGF-b1 (100 pg/ml). All bars represent the
mean6SEM for n=4 samples (* p,0.05 by ANOVA with post-hoc testing).
doi:10.1371/journal.pone.0001914.g001
Table 1. LAP-induced monocyte chemotaxis is blocked by
specific inhibitors of LAP-TSP-1 interactions.
Inhibitor Treatment of
Monocytes
Fold-change in monocyte
recruitment to LAP vs.
‘‘Untreated’’ control P value
Untreated 4.361.0
Anti-LAP IgG 1.360.4 ,0.05
Anti-TGF-b1 IgG 4.360.7 ns
anti-TSP-1 IgG 1.160.1 ,0.01
anti-CD36 IgG 1.260.1 ,0.001
anti-CD47 IgG 6.260.7 ns
Isogenic Control Antibody 3.060.5 ns
LSKL 0.960.2 ,0.01
SLLK 3.360.5 ns
RGD-blocking peptide 6.560.6 ns
Scramble RGD-blocking peptide 8.262.4 ns
UO126 MEK inhibitor 1.260.3 ,0.01
Human monocytes (5610
4/condition) were suspended in Gey’s balanced salt
solution and assayed for their chemotactic response to rhLAP. Recruitment was
assayed by incubating monocytes in modified Boyden chambers for 90 minutes
at 37uC and quantified by counting five high-powered fields of stained
membranes in a blinded fashion and reported as fold-increase of LAP (10 pg/
ml)-induced monocyte chemotaxis compared to monocyte chemotaxis induced
by media alone. rhLAP at 10 pg/ml was chosen based on previous experiments
that determined this dose induced maximal cellular recruitment. These data
represent n=3 (minimum) separate experiments expressed as the mean fold-
change6SEM. Reported p values compare fold-change in monocyte
chemotaxis induced by LAP without and with identified inhibitors.
doi:10.1371/journal.pone.0001914.t001
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LAP, TSP-1 deficient and wild type mice were evaluated for an
LAP-mediated reduction in the allogeneic DTHR in the pinnae.
LAP did not inhibit tetanus-induced DTHR in TSP-1 2/2 mice
(p=0.678), but reduced ear swelling in wild-type control mice
from the same background (p=0.004) (Figure 4B), suggesting the
importance of TSP-1 to the biological activity of LAP.
Discussion
Data presented in this manuscript demonstrates that LAP has
independent biological effects in modulating monocyte recruit-
ment both in vitro and in vivo, and suppressing DTHR in a murine
ear model. LAP promoted the chemotaxis of human monocytes
through a TSP-1 and CD36-mediated pathway; whereas, LAP
suppression of DTH was more dependent on TSP-1 and IL-10.
Figure 2. TGF-b1 is able to inhibit LAP-induced monocyte recruitment. (A) 10 pg/ml of rhLAP (dose with maximal response) was used as the
chemoattractant for freshly isolated human peripheral blood monocytes in chemotaxis chambers and assessed as in previous experiments. Increasing
doses of active rhTGF-b1 were pre-incubated with the chemoattractant prior to exposure to the monocyte suspensions (*, p,0.05 vs. LAP alone). (B)
To compare this to the activity of LAP as an inhibitor of active rhTGF-b1 function in this system, we performed parallel experiments where the
conditions were reversed. Active rhTGF-b1 was used at its maximal effective dose (100 pg/ml) based on prior experiments (data not shown). (*,
p,0.05 vs. TGF-b1 alone) All bars represent the mean6SEM. (C) Assessment of LAP-mediated recruitment independent of TGF-b1 receptor activity in
these experiments was assayed using SB 431542 hydrate, a selective inhibitor of TGF-b type 1 receptor kinases (TGF-b1-receptor inhibitor). Cell
suspensions were preincubated for 20 minutes with 10 mM SB 431542 (optimal dose blocking TGF-b2induced signaling) or DMSO. 10 pg/ml of
rhLAP (dose with maximal response) was used as the chemoattractant for freshly isolated human peripheral blood monocytes in chemotaxis
chambers and assessed as in previous experiments. Increasing doses of active rhTGF-b1 were pre-incubated with the chemoattractant prior to
exposure to the monocyte suspensions (*, p,0.05 vs. LAP alone) (*, p,0.05 vs. TGF-b1 alone). All bars represent the mean6SEM for n=3 samples.
doi:10.1371/journal.pone.0001914.g002
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ascribed to the TGF-b1 molecule itself suggesting a potentially
novel role for LAP in regulating cellular inflammation. In fact, as
suggested by our chemotaxis data, TGF-b1 inhibited monocyte
chemotaxis induced by LAP, suggesting a potential role for TGF-
b1 in suppressing LAP-mediated cellular activation.
In vitro, LAP required TSP-1 and CD36 to recruit monocytes,
while other ligands that interact with TSP-1, like RGD peptides
and CD47, did not appear to mediate these responses. In vivo LAP
utilized an IL-10-dependent pathway to mediate suppression of
the cellular immune response. The importance of IL-10 in the
cellular DTH response has been demonstrated in this model[29]
and its connection to an LAP-initiated process provides an
explanation of how LAP could both induce cellular recruitment
and reduce inflammation. We are focusing on defining the cell of
origin and the mechanism by which LAP involves IL-10 in this in
Figure 3. LAP is able to suppress in vivo cellular inflammation similar to TGF-b1 through interactions with thrombospondin-1. A
transfer DTHR assay was performed with antigen (tetanus toxin) and tested agents (TGF-b1, rhLAP and anti-TGF-b1, LAP or TSP-1). C57BL/6 mice were
sensitized to tetanus toxin (TT) and then tested to confirm they had developed a TT-induced DTHR. DTHR was induced in the pinnae of naı ¨ve C57BL/6
mice with simultaneous injection (35 ml) of antigen and splenocytes (8610
6 cells/condition) harvested from antigen-sensitized mice. DTHR was
quantified by measurement of ear thickness 24 hours after injection. (A) LAP (10 pg) and TGF-b1 (5 ng) were tested for the ability to reduce DTHR
when used alone, with anti-TGF-b1 antibodies (1 mg) or anti-LAP antibodies (1 mg) (*p,0.02 versus tetanus sensitized splenocytes + TT; {p,0.01
versus tetanus sensitized splenocytes + TT, n=5). Similar results were observed when this assay was repeated using C57BL/6 mice that had rejected a
cardiac allograft (DBA/2-.C57BL/6) as a model of transfer DTHR. (B) Anti-TSP-1 antibody or isogenic control IgG (all at 1 mg) were tested for their
ability to interfere with rhLAP suppression of TT-induced DTHR (*p,0.02 versus tetanus sensitized splenocytes + TT; {p,0.01 versus tetanus
sensitized splenocytes + TT, n=3). (C) Transfer DTHR assay was performed with antigen, rhLAP and the inhibitory peptide, LSKL or its scrambled
control SLLK (20 mM) ({p,0.01 versus tetanus-sensitized splenocytes + TT, n=2). (D) To determine if LAP used an IL-10 dependent pathway to inhibit
the DTHR (as previously published) the DTHR transfer assay was repeated with anti-IL-10 antibodies and isotype control. (1 mg each) (*p,0.01 vs.
tetanus-sensitized splenocytes + TT, n=3) All bars represent the mean6SEM. DTHR, delayed-type hypersensitivity response; Ag, Antigen; BKG,
background ear girth.
doi:10.1371/journal.pone.0001914.g003
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local dendritic cells, as dendritic cell exposure to LAP has been
shown to influence T-cell production of IL-10.[14]
The concept of an independent role for LAP in immune
homeostasis has precedent. Investigators have proposed that the
large latent complex of TGF-b1 (TGF-b1+LAP+LTBP1) is not
just a passive sink for active TGFb1, but rather an active sensor of
the matricellular environment.[10] While cellular recruitment
regulated by LAP may not be a direct part of this regulatory
paradigm, our data supports this view. In fact, the early and late
effects of TGF-b1 in some model systems could be interpreted as
the sum of the actions of TGF-b1 plus the independent effects of
LAP.
Several studies indicate that LAP may also be important in
pathophysiologic processes. Experiments in a murine model of
human scleroderma and GVHD indirectly support LAP as an
independent regulator of immune cell function. In these studies,
bone-marrow transplantation was performed in mice to induce
TGF-b1-mediated skin fibrosis and inflammation.[5] The inves-
tigators asked if systemic therapy with recombinant LAP
abrogated the development of skin fibrosis in this animal model.
While the data showed an expected reduction in TGF-b1 signaling
and fibrosis, there was persistent monocytic inflammation in the
skin. Since monocyte recruitment can be a function of TGF-b1o r
LAP, these data suggest that LAP could have had independent
biological activity in this model. Other organ effects were not
reported in these studies. The authors concluded that LAP inhibits
the portion of known TGF-b1 signals that result in fibrosis, but
that TGF-b1 likely signaled through other pathways to mediate
inflammation. However, independent effects of LAP were not
considered.
Recently, a genetic abnormality affecting the function of LAP
was described as the underlying cause of a naturally occurring
human disease called Camurati-Engelmann’s disease (CED). CED
is a disorder associated with abnormal bone growth and multiple
other systemic abnormalities.[30] Two groups recently reported
that this disorder was associated with several missense mutations in
the LAP region of the TGF-b1 gene that affects its ability to bind
to TGF-b1 and confer latency.[31] It is possible that some of the
phenotypic abnormalities in CED patients may be related to
changes in LAP and resultant downstream signaling events.
Our data indicate that the type I repeat region (TSR) of TSP-1
is important to the biological effects of LAP. The associations
between the TSR regions of TSP-1 and LAP have been well
studied and characterized.[32–34] These associations, acting
specifically through the LSKL region of LAP are known to
activate latent TGF-b1 in cell or cell-free systems.[25] Recent
studies clarify how these two molecules interact to effect the
dynamic conformational changes that occur during activation of
latent TGF-b1. L
54SKL in LAP binds to an R
94KPK region of the
active TGF-b1 molecule in the small latent complex.[34] In a
proposed model of TSP-1-mediated activation of latent TGF-b1,
the TSR binds to a VLAL region on the active TGF-b1 molecule
allowing the K
412RFK motif on TSP-1 to compete for binding
with L
54SKL.[33] Adding complexity to the role of TSP-1 in
TGF-b1 activation is the finding that K
412RFK residues on TSP-1
are also critical for the biological function of LAP, which is
disrupted by L
54SKL[25]
Our inhibitor data support the secondary hypothesis that TSP-1
and CD36 are important for some aspects of LAP-mediated
immune cell regulation. This is not surprising as TSP-1, TGF-b1
and CD36 are intimately connected physiologically.[32] Finding
that peptides against the type I repeat region of TSP-1 inhibited
LAP-induced cellular activation confirmed that TSP-1 is critical to
the biological functions of LAP. Blocking CD36, a known receptor
for TSP-1, limited the LAP-mediated effects in a chemotaxis
model of monocyte recruitment. However, blocking CD36 did not
appear as integral to LAP’s ability to block allogeneic DTHR as
there appeared to only be a trend toward modest attenuation in
this system. Our data suggest that the signaling induced by LAP is
more complex than a simple interaction between LAP and CD36
mediated by the type I repeat region of TSP-1. This is based on
the fact that the anti-TSP-1 antibody used to inhibit LAP function
in these studies was the clone A6.1, which targets the C-terminal
collagen type V binding region of TSP-1. Although the exact
binding region of TSP-1 that is targeted by clone A6.1 is not
known, because of the close proximity of the type I repeat region
Figure 4. LAP-induced inflammatory cell recruitment is altered
in TSP-1 deficient (TSP-1 2/2) mice. (A) Bone marrow macro-
phages from wild type C57BL/6 or TSP-12/2 mice were isolated and
assessed for chemotaxis activity using modified Boyden chambers.
Macrophages (5610
4/condition) were suspended serum-free in Gey’s
balanced salt solution and chemotaxis was assayed by counting the
mean of five blinded high-powered fields on the polycarbonate filter
({p,0.001 for the chemotaxis of wild-type vs. TSP-1 2/2 BMM). The
data is expressed as fold-change in the mean compared to control
(media alone)6SEM for two independent studies done in triplicate. (B)
LAP’s ability to affect the direct DTHR was tested in TSP-1 2/2 and
wild-type mice. TSP-1 2/2 and wild-type C57BL/6 mice were sensitized
to tetanus toxin (TT) and then tested to confirm they had developed a
TT-induced DTHR. This direct DTHR assay was performed in the pinnae
of these mice with simultaneous injection (35 ml) of antigen (tetanus
toxin) alone or with rhLAP (10 pg) ({p=0.004 for LAP-treated versus
untreated WT mice, n=3). All bars represent the mean6SEM for two
studies unless otherwise noted. DTHR, delayed-type hypersensitivity
response; TT, tetanus toxin; WT, wild type, BKG, background ear girth.
doi:10.1371/journal.pone.0001914.g004
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is plausible to think the antibody’s presence may interfere with
type I repeat function. Since RGD peptides or anti-CD47 IgG did
not modify the biological activity of LAP, we presume that the
inhibition of LAP function by clone A6.1 was not due to blocking
CD47 or RGD peptide binding regions. Regardless, it is likely that
more than the type I repeat region of TSP-1 is necessary for LAP
to induce target cell activation. TSP-1 may anchor several proteins
together to facilitate signaling as has been shown in other
experimental systems.[35,36]
In summary, this report demonstrates that LAP has biological
activity independent of its parent molecule, TGF-b1, that requires
TSP-1 and to a lesser extent CD36 in human monocytes. These
data provide important support for a critical re-evaluation of the
relationship of LAP to active TGF-b1and its role in biologic
systems. This hypothesis emphasizes the need to understand the
‘‘fate’’ of the LAP after pathophysiologic activation of TGF-b1
and may support investigating it as a novel biological target for
fibrotic and inflammatory human disease.
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